Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 1029 results for "pharma trading company"

CTI BioPharma Reports Third Quarter 2014 Financial Results
Securities Technology Monitor

Cardiome Pharma Makes a Move: Down 3.7%

(Financial News Network On) Cardiome Pharma (NASDAQ:CRME), a company whose shares are moving quickly, is trading 3.7% lower to $7.99. The Dow Jones Industrial Average is now trading fractionally lower to 16,804 and the S&P is trading fractionally ... Individual.com, 4 days ago
[x]  

2 images for "pharma trading company"

Proactive Investors USA, 1 day ago
IBN Live, 3 weeks ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP: OTCQB) | Corbus Pharmaceuticals Commences Trading on OTCQB under Ticker Symbol CRBP

- Corbus Pharmaceuticals Holdings, Inc. ( OTCQB : CRBP ), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare, life-threatening inflammatory ...
 Pink Sheets3 days ago Corbus Pharmaceuticals Commences Trading on OTCQB under Ticker Symbol CRBP  Wall Street Business Network3 days ago Corbus Pharmaceuticals, Inc. Commences Trading On OTCQB Under Ticker Symbol CRBP  BioSpace2 days ago CORS PHAR : Corbus Pharmaceuticals Commences Trading on OTCQB under Ticker Symbol CRBP  4 Traders3 days ago
[x]  

CPhI Pharma Release: Celebrating The Best Of Pharma And Recognizing Companies That Turn Inspiration Into Innovation

) It has become a tradition to recognize pharma innovation at CPhI Worldwide, as CPhI Pharma awards winners driving Pharma's biggest innovations. This year, the prestigious CPhI Pharma Awards celebrate innovators from across four ...
 BioSpace4 days ago

Bliss GVS Pharma falls on poor earnings

Bliss GVS Pharma has currently lost more than 3.5 per cent at Rs 66.55 on the BSE, after the company reported weak set of earnings yesterday. The company posted 8.3 per cent fall in Q2 net profit to Rs 21.46 crore in Q2 September 2014 as against ...
 India Infoline13 hours ago Bliss GVS Pharma declines after weak Q2 results  Business Standard India14 hours ago Bliss GVS Pharma : declines after weak Q2 results  4 Traders6 hours ago

Glenmark Pharma gains on reporting 7% rise in Q2 consolidated net profit

Glenmark Pharmaceuticals is currently trading at Rs. 713.00, up by 1.30 points or 0.18% from its previous closing of Rs. 711.70 on the BSE. The scrip opened at Rs. 720.05 and has touched a high and low of Rs. 722.00 and Rs. 705.90 respectively. So ...
 Indian-Commodity13 hours ago Ajanta Pharma trades jubilantly on reporting 41% rise in Q2 net profit  Arihant Capital1 day ago
Sify

Medicine marketing in Kerala turning into a monopoly of north Indian pharma cos

The medicine marketing in Kerala is gradually becoming the monopoly of big manufacturing companies from north Indian states as small scale units in the state are not able to make a foothold in the field due to lack of support from government. The ...
 PharmaBiz17 hours ago Stock Tips with Trading Updates & Market Recommendations  Press Release Ping2 days ago Pharma stocks in limelight  Equitymaster.com3 days ago Indian markets pare losses  Equitymaster.com2 weeks ago
Business Standard India

AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog

Shares of AMAG Pharmaceuticals, Inc. ( AMAG ) were up 2.1% immediately after the company reported better-than-expected third-quarter 2014 earnings. Third-quarter 2014 earnings of 6 cents per share were better than the Zacks Consensus Estimate of a ...
 Zacks.com5 hours ago Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog  Zacks.com2 days ago Sensex trades 60 points higher; Gail India, Sun Pharma gain [Mint, New Delhi :: ]  BusinessWeek3 days ago Sensex up more than 100 points; Pharma shares rally  Business Standard India3 days ago
[x]  
ADVFN India

MEI Pharma treats first patient in cohort-expansion of phase Ib clinical study-ME-344

MEI Pharma, an oncology company focussed on the clinical development of novel therapies for cancer, announced that the first patient has been dosed in the cohort-expansion stage of the Company's phase Ib clinical study of investigational drug ...
 PharmaBiz1 day ago MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Advances Clinical Study Of Mitochondrial Inhibitor ME-344 In Small Cell Lung And Ovarian Cancers  BioSpace2 days ago MEI Pharma Advances Clinical Study Of Mitochondrial Inhibitor ME-344 In Small Cell Lung And Ovarian Cancers  ADVFN India2 days ago
[x]  

Ajanta Pharma surges 5% on solid Q2

Ajanta Pharma has logged smart gains in the second half of the trading session on the back of strong earnings in the Q2FY15. The company reported 40.9 per cent surge in Q2 net profit at Rs 78.63 crore for the quarter ended September 2014 when ...
 India Infoline1 day ago

Ranbaxy swings back into profit in Q2 at Rs 478 cr

Pharma company Ranbaxy Laboratories is back in black at Rs 478 crore for the quarter ended September 2014. The company reported net loss of Rs 454 crore in the same period a year ago. The consolidated revenue increased 16% to Rs 3,260 crore from Rs ...
 Business Standard India3 days ago Lupin net at Rs630 crore; stock slips  India Infoline3 days ago Ranbaxy Laboratories rallies over 7% in trade as net profit beat Street estimates  Economic Times3 days ago Ranbaxy Q2 net profit at Rs. 478 cr; stock rises  India Infoline3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less